The effect of maternal soluble FMS-like tyrosine kinase 1 during pregnancy on risk of preterm delivery.
(1/14)
(+info)
Management of abnormal serum markers in the absence of aneuploidy or neural tube defects.
(2/14)
(+info)
Clinical utility of noninvasive fetal trisomy (NIFTY) test--early experience.
(3/14)
(+info)
Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci.
(4/14)
(+info)
Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics.
(5/14)
(+info)
Noninvasive prenatal determination of twin zygosity by maternal plasma DNA analysis.
(6/14)
(+info)
Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population.
(7/14)
(+info)
Feasibility study of semiconductor sequencing for noninvasive prenatal detection of fetal aneuploidy.
(8/14)
(+info)